Lack of pharmacokinetic drug-drug interaction between orlistat and cerivastatin

Clinical Drug Investigation

Volumn 19, Issue 1, 2000, Pages 71-73

  Mück, Wolfgang ^a   Adelmann, Holger Georg ^a   Ruf, Thorsten ^a   Unger, Sigrun ^a   Voith, Barbara ^a  

^a BAYER AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CERIVASTATIN; TETRAHYDROLIPSTATIN;

AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIGESTIVE SYSTEM FUNCTION DISORDER; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG TOLERABILITY; HUMAN; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0033973249     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200019010-00009     Document Type: Article

References (13)

1. Bischoff H, Angerbauer R, Boberg M, et al. Preclinical review of cerivastatin sodium - a step forward in HMG-CoA reductase inhibition. Atherosclerosis 1998; 139 Suppl. 1: S7-13
2. Davignon J, Hanefeld M, Nakaya N, et al. Clinical efficacy and safety of cerivastatin: summary of pivotal phase IIb/III studies. Am J Cardiol 1998; 82 (4B): 32J-39J
3. Stein E. Cerivastatin in primary hyperlipidemia - a multicenter analysis of efficacy and safety. Atherosclerosis 1998; 139 Suppl. 1:S15-22
4. Kuhlmann J, Mück W, Bischoff H, et al. Cerivastatin (BAY w 6228): a novel HMG-CoA reductase inhibitor. Cardiovasc Drug Rev 1998; 16(3): 236-63
5. Guerciolini R. Mode of action of orlistat. Int J Obes 1997; 21 (6-22): S12-23
6. Oo C, Akbari B, Lee S, et al. Lack of effect of orlistat on the pharmacokinetics and pharmacodynamics of pravastatin. Clin Pharmacol Ther 1999; 65 (2): 187
7. Quion JA, Jones PH. Clinical pharmacokinetics of pravastatin. Clin Pharmacokinet 1994; 27 (2): 94-103
8. Mück W, Ochmann K, Rohde G, et al. Influence of erythromycin pre- and co-treatment on single-dose pharmacokinetics of the HMG-CoA reductase inhibitor cerivastatin. Eur J Clin Pharmacol 1998; 53: 469-73
9. Krol GJ, Beck GW, Ritter W, et al. LC separation and induced fluorimetric detection of rivastatin in blood plasma. J Pharm Biomed Anal 1993; 11: 1269-75
10. Steinjans VW, Hartmann M, Huber R, et al. Lack of pharmacokinetic interaction as an equivalence problem. J Clin Pharmacol Ther 1991; 29: 323-8
11. European Agency for the Evaluation of Medicinal Products (EMEA), Human Medicines Evaluation Unit. CPMP Note for guidance on the investigation of drug interactions: CPMP/EWP/560/95. London: EMEA, Jun 1998
12. Pan HY, DeVault AR, Brescia A, et al. Effect of food on pravastatin pharmacokinetics and pharmacodynamics. Eur J Clin Pharmacol 1993; 31 (6): 291-4
13. Mück W, Ochmann K, Mazzu A, et al. Biopharmaceutical profile of cerivastatin: a novel HMG-CoA reductase inhibitor. Int J Clin Res 1999; 27 (3): 20-7